Development of immune shift materials by controlling cell mobility

2021 Fiscal Year Final Research Report

• Project/Area Number: 19H04465
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 90120:Biomaterials-related
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Tsuyoshi Kimura 東京医科歯科大学, 生体材料工学研究所, 准教授 (10393216)
• Co-Investigator(Kenkyū-buntansha): 中村 奈緒子 芝浦工業大学, システム理工学部, 准教授 (70754878)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 生体材料 / バイオ界面 / 免疫シフト

Outline of Final Research Achievements

We designed and synthesized an implantable anti-CD25 antibody-immobilized materials (CD25-materials) to suppress tumor growth by removing regulatory T cells (Tregs). The surface of material was graft-polymerized with poly(acrylic acid), and the anti-mouse CD25 antibody was then immobilized. The CD25-material could effectively and selectively capture CD25-positive cells through antigen-antibody interactions. In addition, implantation of the CD25-material into mice subcutaneously demonstrated the Treg-capturing ability with only a weak inflammatory reaction. In tumor-bearing mice, tumor growth was suppressed by subcutaneous implantation of the CD25-material near the tumor for 1 week. These results suggested that the anti-CD25 antibody-immobilized material could capture Tregs in vivo and inhibit tumor proliferation. Further research is needed to facilitate cancer immunotherapy using implantable anti-CD25 antibody-immobilized material as a Treg-capturing device.

Free Research Field

生体材料学

Academic Significance and Societal Importance of the Research Achievements

がん免疫療法に対する新しい治療戦略として、腫瘍周辺の免疫抑制状態を解除する免疫シフトマテリアルの開発を提案した。免疫抑制性細胞である制御性T細胞の本免疫シフトマテリアルを用いた腫瘍近傍からの移動により腫瘍増殖減少を示したことは、空間的細胞制御が免疫状態に関係することを明らかとした点において学術的意義は大きい。また、本免疫シフトマテリアルはがん免疫等の様々な免疫疾患に応用が期待され、社会的意義を有する。